Skip to main content
SpringerLink
Log in

Individualisierte Diabetestherapie zum Schutz vor kognitiven Defiziten

Schützt Pioglitazon bei Typ-2-Diabetes und hohem vaskulären Risiko vor Demenz?

  • Journal club
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Zhou JB et al. Metabolism. 2020; 109: 154265

  2. Heneka MT et al. Ann Neurol. 2015; 78: 284-94

  3. Burns DK et al. Lancet Neurol. 2021; 20: 537-47

  4. https://beta.clinicaltrials.gov/study/NCT04777396

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Klinikum Bremen-Ost, Züricher Straße 40, 28325, Bremen, Germany

    Thomas Duning

Authors
  1. Thomas Duning
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Duning.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duning, T. Schützt Pioglitazon bei Typ-2-Diabetes und hohem vaskulären Risiko vor Demenz?. InFo Neurologie 25, 14–15 (2023). https://doi.org/10.1007/s15005-023-3261-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-023-3261-4

Search

Navigation